vs
Arcosa, Inc.（ACA）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
登士柏西诺德的季度营收约是Arcosa, Inc.的1.3倍（$961.0M vs $716.7M），Arcosa, Inc.净利率更高（7.3% vs -15.2%，领先22.5%），Arcosa, Inc.同比增速更快（7.6% vs 6.2%），登士柏西诺德自由现金流更多（$60.0M vs $55.8M），过去两年Arcosa, Inc.的营收复合增速更高（9.4% vs 0.4%）
Arcosa, Inc.是一家基础设施相关产品及解决方案提供商，业务覆盖建筑、能源、交通三大核心板块，主营公用设施结构件、建筑集料、交通零部件等产品，主要面向北美市场客户，为各类关键基础设施建设项目提供支持。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
ACA vs XRAY — 直观对比
营收规模更大
XRAY
是对方的1.3倍
$716.7M
营收增速更快
ACA
高出1.4%
6.2%
净利率更高
ACA
高出22.5%
-15.2%
自由现金流更多
XRAY
多$4.2M
$55.8M
两年增速更快
ACA
近两年复合增速
0.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $716.7M | $961.0M |
| 净利润 | $52.1M | $-146.0M |
| 毛利率 | 22.9% | 46.1% |
| 营业利润率 | 11.0% | -14.5% |
| 净利率 | 7.3% | -15.2% |
| 营收同比 | 7.6% | 6.2% |
| 净利润同比 | 776.6% | 66.0% |
| 每股收益（稀释后） | $1.06 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACAXRAY
| Q4 25 | $716.7M | $961.0M | ||
| Q3 25 | $797.8M | $904.0M | ||
| Q2 25 | $736.9M | $936.0M | ||
| Q1 25 | $632.0M | $879.0M | ||
| Q4 24 | $666.2M | $905.0M | ||
| Q3 24 | $640.4M | $951.0M | ||
| Q2 24 | $664.7M | $984.0M | ||
| Q1 24 | $598.6M | $953.0M |
净利润ACAXRAY
| Q4 25 | $52.1M | $-146.0M | ||
| Q3 25 | $73.0M | $-427.0M | ||
| Q2 25 | $59.7M | $-45.0M | ||
| Q1 25 | $23.6M | $20.0M | ||
| Q4 24 | $-7.7M | $-430.0M | ||
| Q3 24 | $16.6M | $-494.0M | ||
| Q2 24 | $45.6M | $-4.0M | ||
| Q1 24 | $39.2M | $18.0M |
毛利率ACAXRAY
| Q4 25 | 22.9% | 46.1% | ||
| Q3 25 | 24.1% | 48.8% | ||
| Q2 25 | 22.5% | 52.4% | ||
| Q1 25 | 19.8% | 53.0% | ||
| Q4 24 | 19.3% | 49.3% | ||
| Q3 24 | 21.3% | 52.1% | ||
| Q2 24 | 20.8% | 51.9% | ||
| Q1 24 | 18.6% | 53.1% |
营业利润率ACAXRAY
| Q4 25 | 11.0% | -14.5% | ||
| Q3 25 | 14.1% | -24.1% | ||
| Q2 25 | 12.9% | -13.7% | ||
| Q1 25 | 8.8% | 7.2% | ||
| Q4 24 | 6.5% | -56.2% | ||
| Q3 24 | 5.3% | -48.6% | ||
| Q2 24 | 10.1% | 5.1% | ||
| Q1 24 | 8.9% | 4.4% |
净利率ACAXRAY
| Q4 25 | 7.3% | -15.2% | ||
| Q3 25 | 9.2% | -47.2% | ||
| Q2 25 | 8.1% | -4.8% | ||
| Q1 25 | 3.7% | 2.3% | ||
| Q4 24 | -1.2% | -47.5% | ||
| Q3 24 | 2.6% | -51.9% | ||
| Q2 24 | 6.9% | -0.4% | ||
| Q1 24 | 6.5% | 1.9% |
每股收益（稀释后）ACAXRAY
| Q4 25 | $1.06 | $-0.74 | ||
| Q3 25 | $1.48 | $-2.14 | ||
| Q2 25 | $1.22 | $-0.22 | ||
| Q1 25 | $0.48 | $0.10 | ||
| Q4 24 | $-0.16 | $-2.09 | ||
| Q3 24 | $0.34 | $-2.46 | ||
| Q2 24 | $0.93 | $-0.02 | ||
| Q1 24 | $0.80 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $214.6M | $326.0M |
| 总债务越低越好 | $1.5B | $2.3B |
| 股东权益账面价值 | $2.6B | $1.3B |
| 总资产 | $5.0B | $5.4B |
| 负债/权益比越低杠杆越低 | 0.57× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资ACAXRAY
| Q4 25 | $214.6M | $326.0M | ||
| Q3 25 | $220.0M | $363.0M | ||
| Q2 25 | $189.7M | $359.0M | ||
| Q1 25 | $167.9M | $398.0M | ||
| Q4 24 | $187.3M | $272.0M | ||
| Q3 24 | $756.8M | $296.0M | ||
| Q2 24 | $103.7M | $279.0M | ||
| Q1 24 | $176.5M | $291.0M |
总债务ACAXRAY
| Q4 25 | $1.5B | $2.3B | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | $1.7B | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $699.9M | — | ||
| Q1 24 | $600.6M | — |
股东权益ACAXRAY
| Q4 25 | $2.6B | $1.3B | ||
| Q3 25 | $2.6B | $1.5B | ||
| Q2 25 | $2.5B | $2.0B | ||
| Q1 25 | $2.5B | $2.0B | ||
| Q4 24 | $2.4B | $1.9B | ||
| Q3 24 | $2.4B | $2.5B | ||
| Q2 24 | $2.4B | $3.1B | ||
| Q1 24 | $2.4B | $3.3B |
总资产ACAXRAY
| Q4 25 | $5.0B | $5.4B | ||
| Q3 25 | $5.1B | $5.7B | ||
| Q2 25 | $5.0B | $6.1B | ||
| Q1 25 | $4.9B | $6.0B | ||
| Q4 24 | $4.9B | $5.8B | ||
| Q3 24 | $4.4B | $6.6B | ||
| Q2 24 | $3.8B | $6.9B | ||
| Q1 24 | $3.7B | $7.1B |
负债/权益比ACAXRAY
| Q4 25 | 0.57× | 1.70× | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.68× | — | ||
| Q4 24 | 0.69× | 0.90× | ||
| Q3 24 | 0.51× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.25× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $120.0M | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | $60.0M |
| 自由现金流率自由现金流/营收 | 7.8% | 6.2% |
| 资本支出强度资本支出/营收 | 9.0% | 4.3% |
| 现金转化率经营现金流/净利润 | 2.30× | — |
| 过去12个月自由现金流最近4个季度 | $175.5M | $104.0M |
8季度趋势，按日历期对齐
经营现金流ACAXRAY
| Q4 25 | $120.0M | $101.0M | ||
| Q3 25 | $160.6M | $79.0M | ||
| Q2 25 | $61.2M | $48.0M | ||
| Q1 25 | $-700.0K | $7.0M | ||
| Q4 24 | $248.2M | $87.0M | ||
| Q3 24 | $135.0M | $141.0M | ||
| Q2 24 | $38.3M | $208.0M | ||
| Q1 24 | $80.5M | $25.0M |
自由现金流ACAXRAY
| Q4 25 | $55.8M | $60.0M | ||
| Q3 25 | $121.0M | $40.0M | ||
| Q2 25 | $33.4M | $16.0M | ||
| Q1 25 | $-34.7M | $-12.0M | ||
| Q4 24 | $194.9M | $36.0M | ||
| Q3 24 | $100.6M | $98.0M | ||
| Q2 24 | $-9.3M | $156.0M | ||
| Q1 24 | $26.1M | $-9.0M |
自由现金流率ACAXRAY
| Q4 25 | 7.8% | 6.2% | ||
| Q3 25 | 15.2% | 4.4% | ||
| Q2 25 | 4.5% | 1.7% | ||
| Q1 25 | -5.5% | -1.4% | ||
| Q4 24 | 29.3% | 4.0% | ||
| Q3 24 | 15.7% | 10.3% | ||
| Q2 24 | -1.4% | 15.9% | ||
| Q1 24 | 4.4% | -0.9% |
资本支出强度ACAXRAY
| Q4 25 | 9.0% | 4.3% | ||
| Q3 25 | 5.0% | 4.3% | ||
| Q2 25 | 3.8% | 3.4% | ||
| Q1 25 | 5.4% | 2.2% | ||
| Q4 24 | 8.0% | 5.6% | ||
| Q3 24 | 5.4% | 4.5% | ||
| Q2 24 | 7.2% | 5.3% | ||
| Q1 24 | 9.1% | 3.6% |
现金转化率ACAXRAY
| Q4 25 | 2.30× | — | ||
| Q3 25 | 2.20× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | -0.03× | 0.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.13× | — | ||
| Q2 24 | 0.84× | — | ||
| Q1 24 | 2.05× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACA
| Engineered Structures | $301.1M | 42% |
| Total Construction Materials | $276.8M | 39% |
| Specialty Materials And Asphalt | $110.2M | 15% |
| Construction Site Support | $28.6M | 4% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
